Current progresses of novel natural products and their derivatives/ analogs as anti-Alzheimer candidates: An update

Mini-Reviews in Medicinal Chemistry

Volumn 13, Issue 6, 2013, Pages 870-887

  Fang, Lei ^a,b   Gou, Shaohua ^a   Fang, Xubin ^a   Cheng, Lin ^a   Fleck, Christian ^c  

^a SOUTHEAST UNIVERSITY   (China)

^b CHINA PHARMACEUTICAL UNIVERSITY   (China)

^c FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

Author keywords

Acetylcholinesterase inhibitor; Alzheimer's disease; Antioxidant; Monoamine oxidase inhibitor; Natural product; Neuroprotection

Indexed keywords

ALZHEIMER DISEASE; ANIMALS; ANTIOXIDANTS; BIOLOGICAL AGENTS; CHOLINESTERASE INHIBITORS; DRUG DISCOVERY; HUMANS; MONOAMINE OXIDASE INHIBITORS; NEUROPROTECTIVE AGENTS; PHOSPHORYLATION; TAU PROTEINS;

EID: 84876730642     PISSN: 13895575     EISSN: 18755607     Source Type: Journal    
DOI: 10.2174/1389557511313060009     Document Type: Review

References (97)

1. Ferri, C.; Prince, M.; Brayne, C. Global prevalence of dementia: a delphi consensus study. Lancet, 2005, 366, 2112-2117.
2. Burns, A.; Iliffe, S. Alzheimer's disease. BMJ, 2009, 338, b158.
3. Huang, W.; Sheng R.; Hu, Y. Progress in the development of nonpeptidomimetic BACE 1 inhibitors for Alzheimer's disease. Curr. Med. Chem., 2009, 16, 1806-1820.
4. Cacabelos, R. Pharmacogenomics in Alzheimer's disease. Methods Mol. Biol., 2008, 448, 213-357.
5. Tumiatti, V.; Minarini, A.; Bolognesi, M.L.; Milelli, A.; Rosini, M.; Melchiorre, C. Tacrine derivatives and Alzheimer's disease. Curr. Med. Chem., 2010, 17, 1825-1838.
6. Querfurth, H.W.; LaFerla, F.M. Alzheimer's Disease. N. Engl. J. Med., 2010, 362, 329-44.
7. Decker, M. Hybrid molecules incorporating natural products: Applications in cancer therapy, neurodegenerative disorders and beyond. Curr. Med. Chem., 2011, 18, 1464-1475.
8. Loizzo, M.R.; Tundis, R.; Menichini, F.; Menichini, F. Natural products and their derivatives as cholinesterase inhibitors in the treatment of neurodegenerative disorders: an update. Curr. Med. Chem., 2008, 15, 1209-1228.
9. Viegas, C. Jr.; Bolzani, Vda. S.; Barreiro, E.J.; Fraga, C.A. New anti-Alzheimer drugs from biodiversity: the role of the natural acetylcholinesterase inhibitors. Mini. Rev. Med. Chem., 2005, 5, 915-926.
10. Mecocci, P.; Mariani, E.; Polidori, M.C.; Hensley, K.; Butterfield, D.A. Antioxidant agents in Alzheimer's disease. Cent. Nerv. Syst. Agents Med. Chem., 2008, 8, 48-63.
11. Williams, P.; Sorribas, A.; Howes, M.J. Natural products as a source of Alzheimer's drug leads. Nat. Prod. Rep., 2011, 28, 48-77.
12. da Rocha, M.D.; Viegas, F.P.; Campos, H.C.; Nicastro, P.C.; Fossaluzza, P.C.; Fraga, C.A.; Barreiro, E.J.; Viegas, C. Jr. The role of natural products in the discovery of new drug candidates for the treatment of neurodegenerative disorders II: Alzheimer's disease. CNS Neurol. Disord. Drug Targets, 2011, 10, 251-270.
13. Lilienfeld, S.; Parys, W. Galantamine: additional benefits to patients with Alzheimer's disease. Dement. Geriatr. Cogn. Disord., 2000, 11, 19-27.
14. Eles, E.; Arias, E.; Garcia, A.G.; Lopez, M.G. Galatamine induces neurotransmitter release likely by blocking SK channels: a new mechanism of action for anti-Alzheimer's drugs. Methods Find. Exp. Clin. Pharmacol., 2002, 24, 151-162.
15. Arias, E.; Alés, E.; Gabilan, N.H.; Cano-Abad, M.F.; Villarroya, M.; García, A.G.; López, M.G. Galantamine prevents apoptosis induced by beta-amyloid and thapsigargin: involvement of nicotinic acetylcholine receptors. Neuropharmacology. 2004, 46, 103-14.
16. Marco-Contelles, J.; do Carmo Carreiras, M.; Rodr guez, C.; Villarroya, M.; García, A.G. Synthesis and pharmacology of galantaminetamine. Chem. Rev., 2006, 106, 116-133.
17. Vezenkov, L.T.; Georgieva, M.G.; Danalev, D.L.; Ivanov, T.B.; Ivanova, G.I. Synthesis and characterization of new galanthamine derivatives comprising peptide moiety. Protein Pept. Lett., 2009, 16, 1024-1028.
18. Perissutti, E.; Fiorino, F.; Severino, B.; Frecentese, F.; Massarelli, P.; Nencini, C.; Santagada, V.; Caliendo, G. Synthesis of 6-dglucosyl and 6-nitroxy (-)-galanthamine derivatives as acetylcholinesterase inhibitors. Pharmazie, 2007, 62, 403-405.
19. Sheng, R.; Lin, X.; Jiang, Y.; Li, J.; Shang, Z.; Hu, Y. Design, synthesis, and evaluation of 2-phenoxy-indan-1-one derivatives as acetyl-cholinesterase inhibitors. Bioorg. Med Chem. Lett., 2005, 15, 3834-3837.
20. Jia, P.; Sheng, R.; Zhang, J.; Fang, L.; He, Q.; Yang, B.; Hu, Y. Design, synthesis and evaluation of galanthamine derivatives as acetylcholinesterase inhibitors. Eur. J. Med. Chem., 2009, 44, 772-784.
21. Berkov, S.; Codina, C.; Viladomat, F.; Bastida, J. N-Alkylated galanthamine derivatives: Potent acetylcholinesterase inhibitors from Leucojum aestivum. Bioorg. Med. Chem. Lett., 2008, 18, 2263-2266.
22. Jordis, U.; Froehlich, J.; Treu, M.; Hinschall, M.; Czollner, L.; Kaeltz, B.; Welzig, S. New derivative and analogue of galanthamine. European Patent EP 1181294 B1, 2001.
23. Bartolucci, C.; Haller, L.A.; Jordis, U.; Fels, G.; Lamba, D. Probing Torpedo californica acetylcholinesterase catalytic gorge with two novel bis-functional galanthamine derivatives. J. Med. Chem., 2010, 53, 745-751.
24. Pilger, C.; Bartolucci, C.; Lamba, D.; Tropscha, A.; Fels, G. Accurate prediction of the bound conformation of galanthamine in the active site of Torpedo californica acetylcholinesterase using molecular docking. J. Mol. Graphics Modell., 2001, 19, 288-296.
25. Chang J. Medicinal herbs: drugs or dietary supplements. Biochem. Pharmacol., 2000, 59, 211-219.
26. Little, J.T.; Walsh, S.; Aisen, P.S. An update on huperzine A as a treatment for Alzheimer's disease. Expert Opin. Investig. Drugs, 2008, 17, 209-215.
27. Yan, J.; Sun, L.; Wu, G.; Yi, P.; Yang, F.; Zhou, L.; Zhang, X.; Li, Z.; Yang, X.; Luo, H.; Qiu, M. Rational design and synthesis of highly potent anti-acetylcholinesterase activity huperzine A derivatives. Bioorg. Med. Chem., 2009, 17, 6937-6941.
28. Vanlaer, S.; Voet, A.; Gielens, C.; De Maeyer, M.; Compernolle, F. Bridged 5,6,7,8-tetrahydro-1,6-naphthyridines, analogues of Huperzine A: synthesis, modelling studies and evaluation as inhibitors of acetylcholinesterase. Eur. J. Org. Chem., 2009, 5, 643-654.
29. Holzgrabe, U.; Kapková, P.; Alptüzün, V.; Scheiber, J.; Kugelmann, E. Targeting acetylcholinesterase to treat neurodegeneration. Expert Opin. Ther. Targets, 2007, 11, 161-179.
30. He, X.C.; Feng, S.; Wang, Z.F.; Shi, Y.; Zheng, S.; Xia, Y.; Jiang, H.; Tang, X.C.; Bai, D. Study on dual-site inhibitors of acetylcholinesterase: Highly potent derivatives of bis- and bifunctional huperzine B. Bioorg. Med. Chem., 2007, 15, 1394-1408.
31. Shi, Y.F.; Zhang, H.Y.; Wang, W.; Fu, Y.; Xia, Y.; Tang, X.C.; Bai, D.L.; He, X.C. Novel 16-substituted bifunctional derivatives of huperzine B: multifunctional cholinesterase inhibitors. Acta Pharmacol. Sin., 2009, 30, 1195-1203.
32. Camps, P.; El Achab, R.; Görbig, D.M.; Morral, J.; Munõz-Torrero, D.; Badia, A.; Banõs, J.E.; Vivas, N.M.; Barril, X.; Orozco, M.; Luque, F.J. Synthesis, in vitro pharmacology, and molecular modeling of very potent tacrine-huperzine A hybrids as acetylcholinesterase inhibitors of potential interest for the treatment of Alzheimer's disease. J. Med. Chem., 1999, 42, 3227-3242.
33. Ronco, C.; Sorin, G.; Nachon, F.; Foucault, R.; Jean, L.; Romieu, A.; Renard, P.Y. Synthesis and structure-activity relationship of Huprine derivatives as human acetylcholinesterase inhibitors. Bioorg. Med. Chem., 2009, 17, 4523-4536.
34. Camps, P.; Formosa, X.; Muñoz-Torrero, D.; Petrignet, J.; Badia, A.; Clos, M.V. Synthesis and pharmacological evaluation of huprine tacrine heterodimers: subnanomolar dual Binding site acetylcholinesterase inhibitors. J. Med. Chem., 2005, 48, 1701-1704.
35. Atta-ur-Rahman; Khalid, A.; Sultana, N.; Ghayur, M.N.; Mesaik, M.A.; Khan, M.R.; Gilani, A.H.; Choudhary, M.I. New natural cholinesterase inhibiting and calcium channel blocking quinoline alkaloids. J. Enzyme Inhib. Med. Chem., 2006, 21, 703-710.
36. Fujiwara, M.; Yagi, N.; Miyazawa, M. Acetylcholinesterase inhibitory activity of volatile oil from Peltophorum dasyrachis Kurz ex Bakar (yellow batai) and Bisabolane-type sesquiterpenoids. J. Agric. Food Chem., 2010, 58, 2824-2829.
37. Malla, R.K.; Bandyopadhyay, S.; Spilling, C.D.; Dutta, S.; Dupureur, C.M. The first total synthesis of (±)-cyclophostin and (±)-cyclipostin P: inhibitors of the serine hydrolases acetyl cholinesterase and hormone sensitive lipase. Org. Lett., 2011, 13, 3094-3097.
38. Kurokawa, T.; Suzuki, K.; Hayaoka, T.; Nakagawa, T. Cyclophostin, acetylcholinesterase inhibitor from streptomyces lavendulae. J. Antibiot., 1993, 46, 1315-1318.
39. Bandyopadhyay, S.; Dutta, S.; Spilling, C.D.; Dupureur, C.M.; Rath, N.P. Synthesis and biological evaluation of a phosphonate analog of the natural acetyl cholinesterase inhibitor cyclophostin. J. Org. Chem., 2008, 73, 8386-8391.
40. Dutta, S.; Malla, R.K.; Bandyopadhyay, S.; Spilling, C.D.; Dupureur, C.M. Synthesis and kinetic analysis of some phosphonate analogs of cyclophostin as inhibitors of human acetylcholinesterase. Bioorg. Med. Chem., 2010, 18, 2265-2274.
41. Geissler, T.; Brandt, W.; Porzel, A.; Schlenzig, D.; Kehlen, A.; Wessjohann, L.; Arnold, N. Acetylcholinesterase inhibitors from the toadstool Cortinarius infractus. Bioorg. Med. Chem., 2010, 18, 2173-2177.
42. Tsogoeva, S.B. Recent progress in the development of synthetic hybrids of natural or unnatural bioactive compounds for medicinal chemistry. Mini. Rev. Med. Chem., 2010, 10, 773-793.
43. Markesbery, W.R.; Carney, J.M. Oxidative alterations in Alzheimer's disease. Brain Pathol., 1999, 9, 133-146.
44. Jung, H.A.; Min, B.S.; Yokozawa, T.; Lee, J.H.; Kim, Y.S.; Choi, J.S. Anti-Alzheimer and antioxidant activities of Coptidis Rhizoma alkaloids. Biol. Pharm. Bull., 2009, 32, 1433-1438.
45. Kim, J.; Lee, H.J.; Lee, K.W. Naturally occurring phytochemicals for the prevention of Alzheimer's disease. J. Neurochem., 2010, 112, 1415-1430.
46. Singh, M.; Arseneault, M.; Sanderson, T.; Murthy, V.; Ramassamy, C. Challenges for research on polyphenols from foods in Alzheimer's disease: bioavailability, metabolism, and cellular and molecular mechanisms. J. Agric. Food Chem., 2008, 56, 4855-4873.
47. Wenzel, E.; Somoza, V. Metabolism and bioavailability of transresveratrol. Mol. Nutr. Food Res., 2005, 49, 472-481.
48. Szekeres, T.; Fritzer-Szekeres, M.; Saiko, P.; Jäger, W. Resveratrol and resveratrol analogues--structure-activity relationship. Pharm. Res., 2010, 27, 1042-1048.
49. Jung, J.C.; Lim, E.; Lee, Y.; Kang, J.M.; Kim, H.; Jang, S.; Oh, S.; Jung, M. Synthesis of novel trans-stilbene derivatives and evaluation of their potent antioxidant and neuroprotective effects. Eur. J. Med. Chem., 2009, 44, 3166-3174.
50. Chen, G.; Shan, W.; Wu, Y.; Ren, L.; Dong, J.; Ji, Z. Synthesis and antiinflammatory activity of resveratrol analogs. Chem. Pharm. Bull., 2005, 53, 1587-1590.
51. Meng, X.L.; Yang, J.Y.; Chen, G.L.; Zhang, L.J.; Wang, L.H.; Li, J.; Wang, J.M.; Wu, C.F. RV09, a novel resveratrol analogue, inhibits NO and TNF-alpha production by LPS-activated microglia. Int. Immunopharmacol., 2008, 8, 1074-1082.
52. Olas, B.; Wachowicz, B.; Nowak, P.; Stochmal, A.; Oleszek, W.; Glowacki, R.; Bald, E. Comparative studies of the antioxidant effects of a naturally occurring resveratrol analogue - trans-3,3',5,5'-tetrahydroxy-4'-methoxystilbene and resveratrolagainst oxidation and nitration of biomolecules in blood platelets. Cell Biol. Toxicol., 2008, 24, 331-340.
53. Smith, J.V.; Luo, Y. Studies on molecular mechanisms of Ginkgo biloba extract. Appl. Microbiol. Biotechnol., 2004, 64, 465-472.
54. Shi, C.; Liu, J.; Wu, F.; Yew, D.T. Ginkgo biloba extract in Alzheimer's disease: From action mechanisms to medical practice. Int. J. Mol. Sci., 2010, 8, 107-123.
55. BDeFeudis, F.V.; Papadopoulos, V.; Drieu K. Ginkgo biloba extracts and cancer: a research area in its infancy. Fundam. Clin. Pharmacol., 2003, 17, 405-417.
56. Yao, Z.X.; Han, Z.; Drieu, K.; Papadopoulos, V. Ginkgo biloba extract (Egb 761) inhibits beta-amyloid production by lowering free cholesterol levels. J. Nutr. Biochem., 2004, 5, 749-756.
57. Ramassamy, C.; Longpre, F.; Christen, Y. Ginkgo biloba extract (EGb 761) in Alzheimer's disease: is there any evidence? Curr. Alzheimer Res., 2007, 4, 253-262.
58. Mahadevan, S.; Park, Y. Multifaceted therapeutic benefits of Ginkgo biloba L.: chemistry, efficacy, safety, and uses. J. Food Sci., 2008, 73, R14-R19.
59. Ringman, J.M.; Frautschy, S.A.; Cole, G.M.; Masterman, D.L.; Cummings, J.L. A potential role of the curry spice curcumin in Alzheimer's disease. Curr. Alzheimer Res., 2005, 2, 131-136.
60. Wei, Q.Y.; Chen, W.F.; Zhou, B.; Yang, L.; Liu, Z.L. Inhibition of lipid peroxidation and protein oxidation in rat liver mitochondria by curcumin and its analogues. Biochim. Biophys. Acta, 2006, 1760, 70-77.
61. Baum, L.; Ng, A. Curcumin interaction with copper and iron suggests one possible mechanism of action in Alzheimer's disease animal models. J. Alzheimers Dis., 2004, 6, 367-377.
62. Ono, K.; Hasegawa, K.; Naiki, H.; Yamada, M. Curcumin has potent anti-amyloidogenic effects for Alzheimer's beta-amyloid fibrils in vitro. J. Neurosci. Res., 2004, 75, 742-750.
63. Narlawar, R.; Pickhardt, M.; Leuchtenberger, S.; Baumann, K.; Krause, S.; Dyrks, T.; Weggen, S.; Mandelkow, E.; Schmidt, B. Curcuminderived pyrazoles and isoxazoles: Swiss army knives or blunt tools for Alzheimer's disease? ChemMedChem, 2008, 3, 165-172.
64. Zhao, Z.; Moghadasian, M.H. Chemistry, natural sources, dietary intake and pharmacokinetic properties of ferulic acid: A review. Food Chem., 2008, 109, 691-702.
65. Picone, P.; Bondi, M.L.; Montana, G.; Bruno, A.; Pitarresi, G.; Giammona, G.; Di Carlo, M. Ferulic acid inhibits oxidative stress and cell death induced by Ab oligomers: improved delivery by solid lipid nanoparticles. Free Radic. Res., 2009, 43, 1133-1145.
66. Byeon, S.R.; Jin, Y.J.; Lim, S.J.; Lee, J.H.; Yoo, K.H.; Shin, K.J.; Oh, S.J.; Kim, D.J. Ferulic acid and benzothiazole dimer derivatives with high binding affinity to beta-amyloid fibrils. Bioorg. Med. Chem. Lett., 2007, 17, 4022-4025.
67. Fang, L.; Kraus, B.; Lehmann, J.; Heilmann, J.; Zhang, Y.; Decker, M. Design and synthesis of tacrine-ferulic acid hybrids as multipotent anti-Alzheimer drug candidates. Bioorg. Med. Chem. Lett., 2008, 18, 2905-2909.
68. Di Loreto, S.; Zimmitti, V.; Sebastiani, P.; Cervelli, C.; Falone, S.; Amicarelli, F. Methylglyoxal causes strong weakening of detoxifying capacity and apoptotic cell death in rat hippocampal neurons. Int. J. Biochem. Cell Biol., 2008, 40, 245-257.
69. Chen, Y.J.; Huang, X.B.; Li, Z.X.; Yin, L.L.; Chen, W.Q.; Li, L. Tenuigenin protects cultured hippocampal neurons against methylglyoxal-induced neurotoxicity. Eur. J. Pharmacol., 2010, 645, 1-8.
70. Manikandan, S.; Devi, R.S. Antioxidant property of-asarone against noisestress-induced changes in different regions of rat brain. Pharmacol. Res., 2005, 52, 467-474.
71. Limón, I.D.; Mendieta, L.; Díaz, A.; Chamorro, G.; Espinosa, B.; Zenteno, E.; Guevara, J. Neuroprotective effect of alpha-asarone on spatial memory and nitric oxide levels in rats injected with amyloid-beta(25-35). Neurosci. Lett., 2009, 453, 98-103.
72. Choi, R.C.; Zhu, J.T.; Leung, K.W.; Chu, G.K.; Xie, H.Q.; Chen, V.P.; Zheng, K.Y.; Lau, D.T.; Dong, T.T.; Chow, P.C.; Han, Y.F.; Wang, Z.T.; Tsim, K.W. A flavonol glycoside, isolated from roots of Panax notoginseng, reduces amyloid-beta-induced neurotoxicity in cultured neurons: signaling transduction and drug development for Alzheimer's disease. J. Alzheimers Dis., 2010, 19, 795-811.
73. Lv, J.; Jia, H.; Jiang, Y.; Ruan, Y.; Liu, Z.; Yue, W.; Beyreuther, K.; Tu, P.; Zhang, D. Tenuifolin, an extract derived from tenuigenin, inhibits amyloid-beta secretion in vitro. Acta Physiol., 2009, 196, 419-425.
74. Chauhan, N.B. Effect of aged garlic extract on APP processing and tau phosphorylation in Alzheimer's transgenic model Tg2576. J. Ethnopharmacol., 2006, 108, 385-394.
75. Griffith, T.N.; Varela-Nallar, L.; Dinamarca, M.C.; Inestrosa, N.C. Neurobiological effects of Hyperforin and its potential in Alzheimer's disease therapy. Curr. Med. Chem., 2010, 17, 391-406.
76. Medina, M.A.; Martínez-Poveda, B.; Amores-Sánchez, M.I.; Quesada, A.R. Hyperforin: more than an antidepressant bioactive compound? Life Sci., 2006, 79, 105-111.
77. Cerpa, W.; Hancke, J.L.; Morazzoni, P.; Bombardelli, E.; Riva, A.; Marin, P.P.; Inestrosa, N.C. The hyperforin derivative IDN5706 occludes spatial memory impairments and neuropathological changes in a double transgenic Alzheimer's mouse model. Curr. Alzheimer Res., 2010, 7, 126-133.
78. Zhu, J.T.; Choi, R.C.; Li, J.; Xie, H.Q.; Bi, C.W.; Cheung, A.W.; Dong, T.T.; Jiang, Z.Y.; Chen, J.J.; Tsim, K.W. Estrogenic and neuroprotective properties of scutellarin from Erigeron breviscapus: a drug against postmenopausal symptoms and Alzheimer's disease. Planta Med., 2009, 75, 1489-1493.
79. Hashimoto, M.; Shahdat, H.M.; Yamashita, S.; Katakura, M.; Tanabe, Y.; Fujiwara, H.; Gamoh, S.; Miyazawa, T.; Arai, H.; Shimada, T.; Shido, O. Docosahexaenoic acid disrupts amyloid beta(1-40) fibrillation and concomitantly inhibits amyloid levels in cerebral cortex of Alzheimer's disease model rats. J. Neurochem., 2008, 107, 1634-1646.
80. Fujiwara, H.; Iwasaki, K.; Furukawa, K.; Seki, T.; He, M.; Maruyama, M.; Tomita, N.; Kudo, Y.; Higuchi, M.; Saido, T.C.; Maeda, S.; Takashima, A.; Hara, M.; Ohizumi, Y.; Arai, H. Uncaria rhynchophylla, a Chinese medicinal herb, has potent antiaggregation effects on Alzheimer's beta-amyloid proteins. J. Neurosci. Res., 2006, 84, 427-433.
81. Fujiwara, H.; Tabuchi, M.; Yamaguchi, T.; Iwasaki, K.; Furukawa, K.; Sekiguchi, K.; Ikarashi, Y.; Kudo, Y.; Higuchi, M.; Saido, T.C.; Maeda, S.; Takashima, A.; Hara, M.; Yaegashi, N.; Kase, Y.; Arai, H. A traditional medicinal herb Paeonia suffruticosa and its active constituent 1,2,3,4,6-penta-O-galloyl-beta-D-glucopyranose have potent anti-aggregation effects on Alzheimer's amyloid beta proteins in vitro and in vivo. J. Neurochem., 2009, 109, 1648-1657.
82. Takeuchi, H.; Jin, S.; Wang, J.; Zhang, G.; Kawanokuchi, J.; Kuno, R.; Sonobe, Y.; Mizuno, T.; Suzumura, A. Tumor necrosis factoralpha induces neurotoxicity via glutamate release from hemichannels of activated microglia in an autocrine manner. J. Biol. Chem., 2006, 281, 21362-21368.
83. Takeuchi, H.; Mizoguchi, H.; Doi, Y.; Jin, S.; Noda, M.; Liang, J.; Li, H.; Zhou, Y.; Mori, R.; Yasuoka, S.; Li, E.; Parajuli, B.; Kawanokuchi, J.; Sonobe, Y.; Sato, J.; Yamanaka, K.; Sobue, G.; Mizuno, T.; Suzumura, A. Blockade of gap junction hemichannel suppresses disease progression in mouse models of amyotrophic lateral sclerosis and Alzheimer's disease. PLoS One, 2011, 6, e21108.
84. Bolasco, A.; Carradori, S.; Fioravanti, R. Focusing on new monoamine oxidase inhibitors. Expert Opin. Ther. Patents, 2010, 20, 909-939.
85. Bortolato, M.; Chen, K.; Shih, J.C. Monoamine oxidase inactivation from pathophysiology to therapeutics. Adv. Drug Deliv. Rev., 2008, 60, 1527-1533.
86. Tao, G.; Irie, Y.; Li, D.J.; Keung, W.M. Eugenol and its structural analogs inhibit monoamine oxidase A and exhibit antidepressantlike activity. Bioorg. Med. Chem., 2005, 13, 4777-4788.
87. Borges, F.; Roleira, F.; Mihazes, N.; Santana, L.; Uriarte, E. Simple coumarins and analogues in medicinal chemistry: occurrence, synthesis and biological activity. Curr. Med. Chem., 2005, 12, 887-916.
88. Chimenti, F.; Secci, D.; Bolasco, A.; Chimenti, P.; Granese, A.; Befani, O.; Turini, P.; Alcaro, S.; Ortuso, F. Inhibition of monoamine oxidases by coumarin-3-acyl derivatives: biological activity and computational study. Bioorg. Med. Chem. Lett., 2004, 14, 3697-3703.
89. Matos, M.J.; Viña, D.; Picciau, C.; Orallo, F.; Santana, L.; Uriarte, E. Synthesis and evaluation of 6-methyl-3-phenylcoumarins as potent and selective MAO-B inhibitors. Bioorg. Med. Chem. Lett., 2009, 19, 5053-5055.
90. Chimenti, F.; Secci, D.; Bolasco, A.; Chimenti, P.; Bizzarri, B.; Granese, A.; Carradori, S.; Yáñez, M.; Orallo, F.; Ortuso, F.; Alcaro, S. Synthesis, molecular modeling, and selective inhibitory activity against human monoamine oxidases of 3-carboxamido-7-substituted coumarins. J. Med. Chem., 2009, 52, 1935-1942.
91. Santana, L.; González-Díaz, H.; Quezada, E.; Uriarte, E.; Yáñez, M.; Viña, D.; Orallo, F. Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors. J. Med. Chem., 2008, 51, 6740-6751.
92. Fischer, P.M. The design of drug candidate molecules as selective inhibitors of therapeutically relevant protein kinases. Curr. Med. Chem., 2004, 11, 1563-1583.
93. Moon, M.J.; Lee, S.K.; Lee, J.W.; Song, W.K.; Kim, S.W.; Kim, J.I.; Cho, C.; Choi, S.J.; Kim, Y.C. Synthesis and structure-activity relationships of novel indirubin derivatives as potent antiproliferative agents with CDK2 inhibitory activities. Bioorg. Med. Chem., 2006, 14, 237-246.
94. Beauchard, A.; Ferandin, Y.; Frère, S.; Lozach, O.; Blairvacq, M.; Meijer, L.; Thiéry, V.; Besson, T. Synthesis of novel 5-substituted indirubins as protein kinases inhibitors. Bioorg. Med. Chem., 2006, 14, 6434-6443.
95. Beauchard, A.; Laborie, H.; Rouillard, H.; Lozach, O.; Ferandin, Y.; Le Guével, R.; Guguen-Guillouzo, C.; Meijer, L.; Besson, T.; Thiéry, V. Synthesis and kinase inhibitory activity of novel substituted indigoids. Bioorg. Med. Chem., 2009, 17, 6257-6263.
96. Leclerc, S.; Garnier, M.; Hoessel, R.; Marko, D.; Bibb, J.A., Snyder, G.L.; Greengard, P.; Biernat, J.; Wu, Y.Z.; Mandelkow, E.M.; Eisenbrand, G.; Meijer, L. Indirubins inhibit glycogen synthase kinase-3 beta and CDK5/p25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer's disease: A property common to most cyclin-dependent kinase inhibitors? J. Biol. Chem., 2001, 276, 251-260.
97. Iuvone, T.; De Filippis, D.; Esposito, G.; D'Amico, A.; Izzo, A.A. The spice sage and its active ingredient rosmarinic acid protect PC12 cells from amyloid-beta peptide-induced neurotoxicity. J. Pharmacol. Exp. Ther., 2006, 317, 1143-1149.